Here is Who Picked Incyte Corp (NASDAQ:INCY) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC),Incyte Corp (NASDAQ:INCY) reported that Baker Bros. Advisors has picked up 34,295,011 of common stock as of 2017-04-28.

The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 34,295,011 representing less than 16.7% stake in the company.

For those not familiar with the company, Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

A glance at Incyte Corp (NASDAQ:INCY)’s key stats reveals a current market capitalization of 25.65 Billion based on 204.59 Million shares outstanding and a price at last close of $124.28 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-13, Bienaime picked up 1,000 at a purchase price of $139.66. This brings their total holding to 3,177 as of the date of the filing.

On the sell side, the most recent transaction saw Stein unload 5,000 shares at a sale price of $137.91. This brings their total holding to 14,648.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Incyte Corp (NASDAQ:INCY)
as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported that Celgene European Investment Co Llc. has picked up 624,575 of common stock as of 2017-04-24.

The acquisition brings the aggregate amount owned by Celgene European Investment Co Llc. to a total of 624,575 representing less than 1.3% stake in the company.

For those not familiar with the company, Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

A glance at Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s key stats reveals a current market capitalization of 2.18 Billion based on 47.27 Million shares outstanding and a price at last close of $47.37 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-24 Celgene picked up 624,575 at a purchase price of $49.50. This brings their total holding to 1,856,353 as of the date of the filing.

On the sell side, the most recent transaction saw Cantley unload 509 shares at a sale price of $50.92. This brings their total holding to 91,755.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Ocera Therapeutics Inc. (NASDAQ:OCRX) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocera Therapeutics Inc. (NASDAQ:OCRX) reported that Perceptive Advisors has picked up 2,150,000 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 2,150,000 representing approximately 9.11% stake in the company.

For those not familiar with the company, Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

A glance at Ocera Therapeutics Inc. (NASDAQ:OCRX)’s key stats reveals a current market capitalization of 37.96 Million based on 23.60 Million shares outstanding and a price at last close of $1.45 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-28, Byrnes picked up 3,000 at a purchase price of $1.28. This brings their total holding to 13,000 as of the date of the filing.

On the sell side, the most recent transaction saw Powell unload 11,969 shares at a sale price of $2.53. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocera Therapeutics Inc. (NASDAQ:OCRX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here’s Who Just Picked Up Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Eleven Biotherapeutics Inc. (NASDAQ:EBIO) reported that Flagship Ventures Fund 2007, L.p. has picked up 829,982 of common stock as of 2017-04-07.

The acquisition brings the aggregate amount owned by Flagship Ventures Fund 2007, L.p. to a total of 829,982 representing a 3.4% stake in the company.

For those not familiar with the company, Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

A glance at Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s key stats reveals a current market capitalization of 47.44 Million based on 24.70 Million shares outstanding and a price at last close of $1.98 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-02-11, Flagship picked up 32,912 at a purchase price of $10.00. This brings their total holding to 293,268 as of the date of the filing.

On the sell side, the most recent transaction saw Mccabe unload 1,399 shares at a sale price of $2.10. This brings their total holding to 5,930.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Eleven Biotherapeutics Inc. (NASDAQ:EBIO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Kingstown Capital Partners is Buying Novelion Therapeutics Inc. (NASDAQ:NVLN) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Novelion Therapeutics Inc. (NASDAQ:NVLN) reported that Kingstown Capital Partners, Llc. has picked up 358,460 of common stock as of 2017-04-05.

The acquisition brings the aggregate amount owned by Kingstown Capital Partners, Llc. to a total of 358,460 representing a 1.9% stake in the company.

For those not familiar with the company, Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

A glance at Novelion Therapeutics Inc. (NASDAQ:NVLN)’s key stats reveals a current market capitalization of 195.73 Million based on 18.53 Million shares outstanding and a price at last close of $10.65 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-09-15, Stonepine picked up 14,928 at a purchase price of $1.55. This brings their total holding to 5,778,496 as of the date of the filing.

On the sell side, the most recent transaction saw Axial unload 8,865,036 shares at a sale price of $3.47. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Novelion Therapeutics Inc. (NASDAQ:NVLN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulmatrix Inc. (NASDAQ:PULM) reported that 5am Ventures Llc. has picked up 251,188 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by 5am Ventures Llc. to a total of 251,188 representing less than 1.41% stake in the company.

For those not familiar with the company, Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

A glance at Pulmatrix Inc. (NASDAQ:PULM)’s key stats reveals a current market capitalization of 53.11 Million based on 17.83 Million shares outstanding and a price at last close of $3.23 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-06-15, Mcguire picked up 1,392 at a purchase price of $6.88. This brings their total holding to 52,722 as of the date of the filing.

On the sell side, the most recent transaction saw Oculus unload 922,500 shares at a sale price of $2.75. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulmatrix Inc. (NASDAQ:PULM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Duggan Robert W is Buying Achaogen Inc. (NASDAQ:AKAO) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Achaogen Inc. (NASDAQ:AKAO) reported that Duggan Robert W has picked up 2,035,888 of common stock as of 2017-03-28.

The acquisition brings the aggregate amount owned by Duggan Robert W to a total of 2,035,888 representing a 5.7% stake in the company.

For those not familiar with the company, Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

A glance at Achaogen Inc. (NASDAQ:AKAO)’s key stats reveals a current market capitalization of 892.04 Million based on 35.78 Million shares outstanding and a price at last close of $23.90 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-19, Viswanathan picked up 500,000 at a purchase price of $13.50. This brings their total holding to 5,215,128 as of the date of the filing.

On the sell side, the most recent transaction saw Hillan unload 3,079 shares at a sale price of $26.58. This brings their total holding to 98,422.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Achaogen Inc. (NASDAQ:AKAO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Celgene Switzerland Llc. Picked Juno Therapeutics Inc. (NASDAQ:JUNO) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Juno Therapeutics Inc. (NASDAQ:JUNO) reported that has picked up 10,350,833 of common stock as of 2017-03-27.

The acquisition brings the aggregate amount owned by Celgene Switzerland Llc. to a total of 10,350,833 representing a 9.7% stake in the company.

For those not familiar with the company, Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

A glance at Juno Therapeutics Inc. (NASDAQ:JUNO)’s key stats reveals a current market capitalization of 2.20 Billion based on 106.02 Million shares outstanding and a price at last close of $20.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-10, Evnin picked up 8,000 at a purchase price of $22.11. This brings their total holding to 56,990 as of the date of the filing.

On the sell side, the most recent transaction saw Azelby unload 12,921 shares at a sale price of $24.14. This brings their total holding to 35,719.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Juno Therapeutics Inc. (NASDAQ:JUNO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Skip to content